
FDA advisors approve Moderna mRNA-1010 9-0 after Trump official blocked review
A February refusal to review unraveled into a unanimous VRBPAC vote and fresh data on efficacy, immunogenicity, and safety.
By Lama Al-Rashid·· 3 min
1 briefing · “mRNA-1010”

A February refusal to review unraveled into a unanimous VRBPAC vote and fresh data on efficacy, immunogenicity, and safety.